Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases

References

• Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260.
   PubMed Web of Science ®Google Scholar
• Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country‘s wealth? Ann Rheum Dis. 2014;73(11):2010–2021.
   PubMed Web of Science ®Google Scholar
• Pentek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn‘s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294–6305.
   PubMed Web of Science ®Google Scholar
• Kalo Z, Voko Z, Ostor A, et al. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. J Mark Access Health Policy. 2017;5(1):1345580.
   PubMedGoogle Scholar
• Bergstra SA, Branco JC, Vega-Morales D, et al. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Ann Rheum Dis. 2018;
   Web of Science ®Google Scholar
• Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit. 2011;17(4):SR1–13.
   PubMed Web of Science ®Google Scholar
• Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728–1737.
   PubMed Web of Science ®Google Scholar
• D‘Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn‘s disease: an open randomised trial. Lancet. 2008;371(9613):660–667.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn‘s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390(10114):2779–2789.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–382.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1 year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2 year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017;76(8):1348–1356.
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–3443.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541–548.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Keystone E, Greenberg JD, et al. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. Rheumatology (Oxford). 2017;56(7):1095–1101.
   PubMed Web of Science ®Google Scholar
• Moots RJ, Mays R, Stephens J, et al. Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs. Clin Exp Rheumatol. 2015;33(5):737–745.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn‘s disease. J Gastroenterol. 2017;52(5):535–554.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm. 2019;15(3):310–317.
   PubMed Web of Science ®Google Scholar
• Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Rencz F, Pentek M, et al. A budget impact model for biosimilar infliximab in Crohn‘s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–125.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533–544.
   PubMed Web of Science ®Google Scholar
• NHS England. NHS set to save record £300 million on the NHS’s highest drug spend 2018 [cited 2018 November 30]. Available from: https://www.england.nhs.uk/2018/11/nhs-set-to-save-record-300-million-on-the-nhss-highest-drug-spend/
   Google Scholar
• U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product 2015 [cited 2019 Feb 03]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
   Google Scholar
• EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. [cited 2015 September 11]. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
   Google Scholar
• Goncalves J, Araujo F, Cutolo M, et al. Biosimilar monoclonal antibodies: preclinical and clinical development aspects. Clin Exp Rheumatol. 2016;34(4):698–705.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Prescribing Biosimilar and Interchangeable Products [ cited 2018 December]. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580430.htm
   Google Scholar
• Araújo FC, Fonseca JE, Goncalves J. Switching to biosimilars in inflammatory rheumatic conditions: current knowledge. EMJ Rheumatol. 2018;5(1):66–74.
   Google Scholar
• Numan S, Faccin F. Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies. Adv Ther. 2018;35(9):12951332.
   PubMed Web of Science ®Google Scholar
• Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49(1):31–40.
   PubMed Web of Science ®Google Scholar
• Toussirot E, Marotte H. Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? RMD Open. 2017;3(2):e000492.
   PubMed Web of Science ®Google Scholar
• Schimizzi GF. Biosimilars from a practicing rheumatologist perspective: an overview. Autoimmun Rev. 2016;15(9):911–916.
   PubMed Web of Science ®Google Scholar
• Kirchhoff CF, Wang XM, Conlon HD, et al. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–2705.
   PubMed Web of Science ®Google Scholar
• Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018;47(5):741–748.
   PubMed Web of Science ®Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74(5):655–661.
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561–567.
   PubMed Web of Science ®Google Scholar
• Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12 month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47(3):356–363.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Biosimilars in the EU 2017. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
   Google Scholar
• Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160–2172.
   PubMed Web of Science ®Google Scholar
• Beck M, Michel B, Rybarczyk-Vigouret MC, et al. Rheumatologists‘ perceptions of biosimilar medicines prescription: findings from a French web-based survey. BioDrugs. 2016;30(6):585–592.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2):e000710.
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–696.
   PubMed Web of Science ®Google Scholar
• Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4(2):209–218.
   PubMed Web of Science ®Google Scholar
• Rezk MF, Pieper B. To see or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. Adv Ther. 2018;35(6):749–753.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Choe JY, Shim SC, et al. Switching to biosimilars in the treatment of rheumatic diseases. Expert Rev Clin Immunol. 2018;14(7):557–571.
   PubMed Web of Science ®Google Scholar
• Hoivik ML, Buer LCT, Cvancarova M, et al. Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53(6):692–699.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Alten R, Puig L, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32(5):397–404.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van Den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60–68.
   PubMed Web of Science ®Google Scholar
• Odinet JS, Day CE, Cruz JL, et al. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952–959.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11(1):26–34.
   PubMed Web of Science ®Google Scholar
• British Association of Dermatologists. Position statement on biosimilars 2017 [ cited 2018 July 2]. Available from: http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=5842
   Google Scholar
• Egeth M, Soosaar J, Nash P, et al. Patient and healthcare professionals preference for Brenzys vs. Enbrel autoinjector for rheumatoid arthritis: a randomized crossover simulated-use study. Adv Ther. 2017;34(5):1157–1172.
   PubMed Web of Science ®Google Scholar
• Thakur K, Biberger A, Handrich A, et al. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in Europe. Rheumatol Ther. 2016;3(2):245–256.
   PubMed Web of Science ®Google Scholar
• Thakur K, Biberger A, Handrich A, et al. Perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: a new European union-approved etanercept biosimilar (Benepali®) versus etanercept (Enbrel®) – findings from a nurse survey in Europe. Rheumatol Ther. 2016;3(1):77–89.
   PubMed Web of Science ®Google Scholar
• FDA. Biosimilars 2017 [cited 2018 July 2]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm
   Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14(1):22–31.
   PubMed Web of Science ®Google Scholar
• Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56(suppl_4):iv49–iv62.
   PubMed Web of Science ®Google Scholar
• Inotai A, Prins CPJ, Csanadi M, et al. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017;17(8):915–926.
   PubMed Web of Science ®Google Scholar
• Barbier L, Ebbers H, Declerck P, et al. The safety and efficacy of switching between reference biologicals and biosimilars: a systematic review. Presented at ISPOR, Barcelona, Spain. 2018. Poster PMU4.
   Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52 week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52 week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562–1574.
   PubMed Web of Science ®Google Scholar
• Cohen S, Pablos JL, Zhang N, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study. Arthritis Rheumatol. 2016;68(suppl):10.
   Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914–921.
   PubMed Web of Science ®Google Scholar
• Hodge J, Tang H, O’Connor P, et al. Switching from adalimumab to CHS-1420: a randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis. Arthritis Rheumatol. 2017;69:abstr2879.
   Web of Science ®Google Scholar
• Genovese MC, Glover J, Matsunaga N, et al. Efficacy, safety and immunogenicity in randomized, double-blind (DB) and open-label extension (OLE) Studies comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product (Humira®; RP) in patients (pts) with active rheumatoid arthritis (RA) (abstract 2799). Arthritis Rheumatol. 2017;69(suppl):10.
   Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr., et al. Phase 3 randomised study of the proposed biosimilar adalimumab GP2017 in psoriasis – impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70(6):832–840.
   PubMed Web of Science ®Google Scholar
• EU Clinical Trials Register. A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety, and immunogenicity of MSB11022 compared with European Union-approved Humira® in subjects with moderate to severe chronic plaque psoriasis [cited 2018 December]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003287-37/results
   Google Scholar
• EU Clinical Trials Register. A randomized, double-blind, parallel-group, multicenter study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira in patients with moderate to severe active rheumatoid arthritis [cited 2018 December]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003433-10/results
   Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77(2):234–240.
   PubMed Web of Science ®Google Scholar
• Matsuno H, Matsubara T. A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Mod Rheumatol. 2018;1–26.
   PubMed Web of Science ®Google Scholar
• Kay J, Chopra A, Lassen C, et al. FRI0117: BOW015, a biosimilar infliximab: disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2015;74(Suppl 2):462–463.
   Google Scholar
• Gerdes S, Thaci D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30 week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32(3):420–427.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Schulze-Koops H, Buch M, et al. FRI0129 Switch between reference etanercept (ETN) and gp2015, an etanercept biosimilar, did not impact efficacy and safety in patients with moderate-to-severe rheumatoid arthritis: 48 week results from the phase 3 equira study. Ann Rheum Dis. 2018;77(Suppl 2):609.
   Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017; DOI:10.1136/annrheumdis-2017-211591
   Web of Science ®Google Scholar
• Song YW, Matsuno H, Park M-C, et al. AB0456 Efficacy and safety of switching from etanercept reference product to lbec0101 (ETANERCEPT BIOSIMILAR) compared with continuing lbec0101 in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(Suppl 2):1389–1390.
   Web of Science ®Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56 week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31(4):369–377.
   PubMed Web of Science ®Google Scholar
• Tony HP, Kruger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88–94.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–363.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamanaka H, Takeuchi T, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237–245.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102 week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346–354.
   PubMed Web of Science ®Google Scholar
• Goll GL, Jorgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Kim Y, Ye BD, Pesegova M, et al. Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active crohn’s disease: 1 year maintenance and switching results. J Crohn‘s Colitis. 2017;11(Suppl_1):S62.
   Google Scholar
• Ye BD, Kim YH, Pesegova M, et al. 814 - phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn‘s disease: 1 year maintenance and switching results. Gastroenterology. 2018;154(6):S-167–S-168.
   Google Scholar
• Volkers A, Jansen J. P0409 SIMILAR trial – efficacy of infliximab-biosimilar compared to infliximab-biological in patients with inflammatory bowel disease in remission – a randomized, controlled, double blind, phase 4 noninferiority trial. United Eur Gastroenterol J. 2017;5:A307.
   Google Scholar
• U.S Food and Drug Administration (FDA). Considerations in demonstrating interchangeability with a reference product guidance for industry. DRAFT GUIDANCE. 2017 [cited 2018 July 2]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
   Google Scholar
• European Medicines Agency. EPAR summary for the public – remsima 2013 [cited 2018 July 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002576/WC500150872.pdf
   Google Scholar
• Smits LJT, van Esch AAJ, Derikx L, et al. Drug survival and immunogenicity after switching from remicade to biosimilar CT-P13 in inflammatory bowel disease patients: two-year follow-up of a prospective observational cohort study. Inflamm Bowel Dis. 2018; DOI:10.1093/ibd/izy227
   Web of Science ®Google Scholar
• European Medicines Agency. Benepali CHMP assessment report 2015 [cited December 2018]. Available from: https://www.ema.europa.eu/documents/assessment-report/benepali-epar-public-assessment-report_en.pdf
   Google Scholar
• Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. one-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2018.
   Web of Science ®Google Scholar
• Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41(1):155–173 e13.
   PubMed Web of Science ®Google Scholar
• British Society of Rheumatology. Position statement: biosimilar medicines 2017 [cited 2018 July 2]. Available from: https://www.rheumatology.org.uk/Portals/0/Policy/Policy%20Statements/Biosimilars.pdf
   Google Scholar
• Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165–174.
   PubMed Web of Science ®Google Scholar
• European Specialist Nurses Organisations (ESNO). Switch management between similar biological medicines: a communication and information guide for nurses 2017 [cited 2018 August]. Available from: http://www.esno.org/assets/biosimilar-nurses-guideline-final.pdf
   Google Scholar
• Medicines for Europe. Positioning statements on physician-led switching for biosimilar medicines 2018 [cited 2018 August]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2017/03/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf
   Google Scholar
• European Association of Hospital Pharmacists. EAHP position paper on biosimilar medicines 2018 [cited 2018 July 2]. Available from: http://www.eahp.eu/practice-and-policy/biosimilar
   Google Scholar
• Moura CS, Abrahamowicz M, Beauchamp ME, et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther. 2015;17:197.
   PubMed Web of Science ®Google Scholar
• Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn‘s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3–13.
   PubMed Web of Science ®Google Scholar
• NHS England. Commissioning framework for biological medicines (including biosimilar medicines) 2017 [cited 2018 August 16]. Available from: https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf
   Google Scholar
• Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609–616.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PLoS One. 2017;12(12):e0190147.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Biosimilar medicines in the EU [cited 2018 December]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines
   Google Scholar
• Standing committee of People with Arthritis and Rheumatism (PARE). Biosimilars: what do patients need to consider? 2015. Available from: https://www.eular.org/myUploadData/files/Biosimilars_2015.pdf
   Google Scholar
• Tweehuysen L, Huiskes VJB, van Den Bemt BJF, et al. FRI0200 Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. Ann Rheum Dis. 2017;76(Suppl 2):557.
   Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24.
   Web of Science ®Google Scholar
• Michetti P, Weinman J, Mrowietz U, et al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the global ALIGN study. Adv Ther. 2017;34(1):91–108.
   PubMed Web of Science ®Google Scholar
• Broekman M, Coenen MJH, Wanten GJ, et al. Patients‘ beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2018;30(2):167–173.
   PubMed Web of Science ®Google Scholar
• Petitdidier N, Gagniere C, Rentien AL, et al. P528 patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: a 12 month prospective observational cohort study. J Crohns Colitis. 2018;12(Supp 1):S373–S374.
   Google Scholar